Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.52−0.11 (-6.75%)
Close on Nov 17, 2026Market cap $93.66MP/E –Yield –
Voyager Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Voyager Therapeutics's pe ratio was 9.4× on Jan 31, 2025, against 2.9× a year earlier. Over the last 4 years it ranged from 0.3× to 45.5×, with a median of 5.0×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Jan 31, 2025 | 9.4× | −0.4 |
| 2024 | Dec 31, 2024 | 9.8× | +2.9 |
| 2023 | Dec 29, 2023 | 6.9× | −1.0 |
| 2021 | Oct 29, 2021 | 7.9× | +1.0 |
| 2020 | Dec 31, 2020 | 6.9× | −6.0 |
| 2017 | Jul 31, 2017 | 12.9× | +5.3 |
| 2016 | Dec 30, 2016 | 7.6× | +6.9 |
| 2015 | Dec 31, 2015 | 0.7× | – |
See a number that looks wrong?